drugset / Trial / NCT01227252

A Safety Study of LY2886721 Multiple Doses in Healthy Subjects

NCT01227252 ↗

Phase 1 Completed 42 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindBasic science

Summary

This is a Phase 1 study in healthy subjects to evaluate the safety and tolerability of LY2886721 multiple doses, how the body handles the drug, and the drug's effect on the body.

Timeline

Start
2010-12
Primary completion
2011-04
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject LY2886721 Small molecule 5 mg Oral
Subject LY2886721 Small molecule 35 mg Oral

Indications